DOCSLIB.ORG

Non-Surgical Interventions for Threatened and Recurrent Miscarriages Tien J C, Tan T Y T

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Non-Surgical Interventions for Threatened and Recurrent Miscarriages Tien J C, Tan T Y T Review Article Singapore Med J 2007; 48 (12) : 1074 CME Article Non-surgical interventions for threatened and recurrent miscarriages Tien J C, Tan T Y T ABSTRACT occurring in 12%–30% of all clinical pregnancies,(1-3) Many surgical and non-surgical inter- and even more if unrecognised biochemical pregnancies ventions are used in the management of are included.(4) A threatened miscarriage is defined threatened and recurrent miscarriages. as vaginal bleeding, usually painless, that occurs in Evidence-based management of recurrent the first 24 weeks in a viable pregnancy without miscarriages requires investigations into cervical dilatation. It is common, especially in the first the underlying aetiology. When a specific trimester, occurring in 14%–21% of all pregnancies.(1,5) cause is identified, directed treatment Recurrent miscarriages are classically defined as three may reduce miscarriage rates. Combined or more consecutive miscarriages. It has been estimated aspirin and heparin for antiphospholipid that 0.5%–1% of women suffer from recurrent syndrome, and screening and treatment miscarriages. More recently, investigations and of bacterial vaginosis between ten and management similar to that for recurrent miscarriages 22 weeks of pregnancy with clindamycin, have been started for women who suffer from two are the only interventions proven to be consecutive miscarriages. This latter group would useful in randomised controlled trials include a larger percentage (2%) of women.(6) (RCTs). The use of periconceptional metformin for polycystic ovarian (PCO) Causes of miscarriages syndrome is promising, though data from Traditional thinking dictates that there is a single cause RCTs are still required. The use of heparin for a miscarriage or recurrent miscarriages. More in inherited thrombophilias, bromocriptine recently, a multifactorial approach to the problem in hyperprolactinaemia and luteinising has been encouraged. In such an approach, all possible hormone suppression in fertile patients with causes of pregnancy loss are considered, and their PCO syndrome are more controversial. In cumulative effects, when exceeding the threshold, threatened miscarriages, or when no cause contribute to a miscarriage.(7) Consideration of the is found, treatment becomes empirical. timing of the miscarriage is important, as different Supportive care may reduce miscarriage causes of miscarriage tend to manifest at different Yong Loo Lin rates. Dydrogesterone, a progesterone School of Medicine, periods of gestation. In first trimester miscarriages, National University derivative, may further reduce miscarriage important causes include chromosomal abnormalities, of Singapore, (8) 10 Medical Drive, rates. Bed rest and avoidance of sexual which occur in about 70% of the cases; maternal Singapore 117597 intercourse, though commonly advised, diseases, including poorly-controlled diabetes mellitus;(9) Tien JC are of no proven benefit. Use of uncontrolled thyroid disease,(10) severe systemic lupus Medical Student uterine relaxing agents, human chorionic (11) (12) erythematosus and antiphospholipid syndrome; Raffles Women’s gonadotrophin, immunotherapy and vitamins poor maternal lifestyle habits (including alcohol Centre, Raffles Hospital, remain controversial in idiopathic recurrent consumption, smoking and use of illicit drugs); and 585 North miscarriages. Bridge Road, exposure to non-steroidal anti-inflammatory drugs #12-00, (NSAIDs) around the time of conception.(13) Second Singapore 188770 Keywords: human chorionic gonadotrophin, trimester miscarriages, on the other hand, are more Tan TYT, MBBS, miscarriage, prospective miscarriage risk, commonly caused by specific types of congenital uterine MMed, MRCOG Consultant and recurrent miscarriage, threatened miscarriage anomalies;(14) cervical incompetence;(15) maternal Foetal Maternal Medicine Specialist Singapore Med J 2007; 48(12):1074–1090 infections;(16) maternal thrombophilic states, such as inherited thrombophilias(17) and antiphospholipid Correspondence to: Dr Tony Tan (18) (8) INTRODUCTION syndrome; and also chromosomal abnormalities, Tel: (65) 6311 1230 Miscarriage refers to the loss of a pregnancy before which account for up to 20% of foetal losses during Fax: (65) 6311 1170 Email: tan_tony@ 24 weeks. It is a common complication of pregnancy, this period. rafflesmedical.com Singapore Med J 2007; 48 (12) : 1075 Fig. 1 Graph shows prospective risk of miscarriage according to the gestational age. Patients with recurrent miscarriages deserve Past obstetric history and miscarriage risk special attention, as the risk of recurrence is higher The impact of previous reproductive history on the and the causes tend to be different from sporadic current pregnancy is relevant because many women miscarriages. There has been no difference found in with previous miscarriage(s) will be anxious about the prevalence and frequency of aetiological how this affects them. In comparison to the baseline factors between those with two or three consecutive risk of miscarriage in the general obstetric population miscarriages.(19) This supports the initiation of of between 12%–30%,(1-3) the risk of miscarriage investigations in women who have had only two in women who have never had a miscarriage or are consecutive miscarriages. The recommended primigravida, is low at 4%–5%.(23) However, in women investigations for recurrent miscarriages are listed with a history of miscarriage, the risks are significantly in Table I. However, it remains an unfortunate fact increased. In a woman who has experienced one, two, that in half of the women suffering from recurrent three and four miscarriages, the risk of a miscarriage miscarriages, a possible aetiological cause is never in the next pregnancy is 19%,(23) 24%, 30% and 40%, identified, even after exhaustive investigations.(19) respectively.(24,25) Risk of miscarriage Prospective miscarriage risk depends on gestational age The baseline risk of miscarriage in any pregnancy is A useful piece of information to both clinicians and dependent on parental age, past obstetric history and parents would be the prospective miscarriage risk for gestational age. each gestational week. This concept of prospective risk has been similarly used for stillbirths.(26,27) The Parental age and miscarriage risk prospective risk is derived from the number of It is well-known that the risk of miscarriage increases prospective miscarriages occurring from week N with increased maternal age; a pregnancy at the onwards, divided by the remaining pregnancies on maternal age of 40 years will incur double the week N (Fig. 1). We calculated this from the raw data, risk of miscarriage when compared to one at a available from a large community prospective study, maternal age of 20 years.(20) More recently, it of 550 pregnancies seen by general practitioners has also been shown that the risk of miscarriage in a health centre in the United Kingdom. A major also increases with increased paternal age; a paternal limitation of the prospective risks of miscarriage age of above 40 years incurs 1.6 times the risk of derived from this population is that the gestational miscarriage when compared to a paternal age of age at miscarriage is taken as the week in which 25–29 years.(21,22) the woman presented with a miscarriage. While the Singapore Med J 2007; 48 (12) : 1076 Table I. Causes and recommended investigations for recurrent miscarriages.(7,19) Causes Diagnosis Recurrent foetal chromosomal Karyotype of miscarried foetus(es), if possible, and peripheral blood karyotyping of couple. abnormalities, especially unbalanced chromosomal translocations Uterine abnormalities Saline infusion pelvic ultrasonography / hysterosalpingography (HSG) / hysteroscopy / sonohysteroscopy. Uncontrolled thyroid disease fT4 and TSH (if symptomatic). Uncontrolled diabetes mellitus Random blood glucose / OGTT with or without HbA1c (if symptomatic). Polycystic ovary syndrome Clinical diagnostic criteria (2 out of 3):(62) 1. Oligo- or anovulation. 2. Clinical and/or biochemical signs of hyperandrogenism. 3. Polycystic ovaries on ultrasonography. After the exclusion of other aetiologies, such as congenital adrenal hyperplasia, androgen secreting tumours and Cushing’s syndrome. Antiphospholipid antibodies Lupus anticoagulant (LAC). IgG and IgM anticardiolipin antibodies (ACA). Inherited thrombophilias Protein S assay, protein C assay, activated protein C resistance assay, antithrombin III assay, factor V leiden, total homocysteine. Bacterial vaginosis High vaginal swab. absolute risks reflected in Fig. 1 cannot be used to Table II. Risk of miscarriage (%) according to gestational age and amount of bleeding. counsel patients usefully, it is important to understand Amount of bleeding Gestational age (weeks) the concept of prospective risk of miscarriage and to 5–6 7–9 10–12 appreciate the trend of decreasing prospective risk of miscarriage with increasing gestational age. Light No data 1%(5) available Moderate 29%(29) No data Prognosis of threatened miscarriage with 9.3%(30) available expectant management Severe 2%(5) There are many other causes of vaginal bleeding during early viable intrauterine pregnancy, besides the more common diagnosis of threatened miscarriage. These include cervical erosions and/or polyps, decidual 2,094 patients with light bleeding and 252 patients with reaction of the cervix, implantation bleed and heavy bleeding. The rate of foetal demise in the event vaginitis.(28) The prognosis of a threatened miscarriage of light bleeding
Load more

Recommended publications
  • Multi-Drug Rapid Test Panel with Adulteration (Urine)
    6-mono-aceto-morphine in urine is 3-7 days. Multi-Drug Rapid Test Panel with 6-MAM 10 Adulteration (Urine) (6-MAM10) The Multi-Drug Rapid Test Panel yields a positive result when the concentration of (±) 3,4-Methylenedioxy- (±) 3,4-Methylenedioxy- benzodiazepines in urine exceeds detective level. Package Insert 500 Buprenorphine (BUP) Amphetamine(MDA500) Amphetamine Instruction Sheet for testing of any combination of the following drugs: Ethyl- β-D-Glucuronide(ETG500) Ethyl- β -D-Glucuronide 500 Buprenorphine is a potent analgesic often used in the treatment of opioid addiction. The drug is ACE/AMP/BAR/BZO/BUP/COC/THC/MTD/MET/MDMA/MOP/MQL/OPI/PCP/PPX/TCA/TML/K sold under the trade names Subutex™, Buprenex™, Temgesic™ and Suboxone™, which ET/OXY/COT/EDDP/FYL/K2/6-MAM/MDA/ETG/CLO/LSD/MPD/ZOL Ethyl- β-D-Glucuronide(ETG1,000) Ethyl- β -D-Glucuronide 1,000 contain Buprenorphine HCl alone or in combination with Naloxone HCl. Therapeutically, Including Specimen Validity Tests (S.V.T.) for: Clonazepam(CLO 400) Clonazepam 400 Buprenorphine is used as a substitution treatment for opioid addicts. Substitution treatment is a Oxidants/PCC, Specific Gravity, pH, Nitrite, Glutaraldehyde and Creatinine Clonazepam(CLO 150) Clonazepam 150 form of medical care offered to opiate addicts (primarily heroin addicts) based on a similar or A rapid test for the simultaneous, qualitative detection of multiple drugs and drug metabolites in identical substance to the drug normally used. In substitution therapy, Buprenorphine is as human urine. For healthcare professionals including professionals at point of care sites. Lysergic Acid Diethylamide (LSD) Lysergic Acid Diethylamide 20 effective as Methadone but demonstrates a lower level of physical dependence.
    [Show full text]
  • COMPARISON of ORAL DYDROGESTERONE and INTRAMUSCULAR PROGESTERONE in the TREATMENT of THREATENED ABORTION -..:: Biomedica
    ORIGINAL ARTICLE COMPARISON OF ORAL DYDROGESTERONE AND INTRAMUSCULAR PROGESTERONE IN THE TREATMENT OF THREATENED ABORTION QING G., HONG Y., FENG X. AND WEI R. Northwest Women’s Hospital, Xian City, Shanxi Province, China ABSTRACT Background and Objective: Threatened abortion is a common condition and presents with varied cli- nical manifestations. The aim of the study was to observe and analyze the efficacy and safety of dydro- gesterone in threatened abortion. Methods: One hundred and seventy two pregnant women with early – threatened abortion diagnosed during prenatal care in Northwest Women’s Hospital from January 2012 to December 2013, were sele- cted and randomly divided into dydrogesterone group and the progesterone group. Patients received either oral dydrogesterone or progesterone injected intramuscularly, respectively. The clinical efficacy and safety of both drugs were observed. Results: There were no significant differences in age, gravidity, parity and gestational age between the two groups (p> 0.05) and there was no significant difference in progesterone levels following treatment (p > 0.05). There were no significant differences in the success rate of fetus protection, abortion rate and treatment time between the groups (p > 0.05). Conclusion: Dydrogesterone and progesterone have significant beneficial effects in the treatment of threatened abortion, and they are easy to use and safe. Keywords: Threatened abortion; Dydrogestrone; Progesterone injection. INTRODUCTION gen and has a significant role in the prevention of early Threatened abortion is a common condition, and the contractions of the myometrium.4 It plays a key role in clinical manifestations are as follows: vaginal bleeding, inducing a protective immunomodulatory effect on the with or without lower abdominal pain, non-dilatation embryo.
    [Show full text]
  • Comparison of the Efficacy of Tibolone and Transdermal Estrogen in Treating Menopausal Symptoms in Postmenopausal Women
    https://doi.org/10.6118/jmm.19205 J Menopausal Med 2019;25:123-129 pISSN: 2288-6478, eISSN: 2288-6761 ORIGINAL ARTICLE Comparison of the Efficacy of Tibolone and Transdermal Estrogen in Treating Menopausal Symptoms in Postmenopausal Women Hyun Kyun Kim, Sung Hye Jeon, Ki-Jin Ryu, Tak Kim, Hyuntae Park Department of Obstetrics and Gynecology, Korea University College of Medicine, Seoul, Korea Objectives: This study aimed to compare the efficacy of tibolone and transdermal estrogen in treating menopausal symptoms in postmenopausal women with an intact uterus. Methods: Overall, 26 women consumed tibolone orally and 31 women received transdermal estrogen gel mixed with progestogen. The menopause rating scale (MRS) was used to assess their menopausal symptoms at their first outpatient visit and 6 months later. Results: The transdermal estrogen group showed significant improvements in more items of the MRS questionnaire. There was a favorable change in body weight in the transdermal estrogen group compared with that in the tibolone group. Depressive mood, irritability, physical and mental exhaustion, sexual and bladder problems, and joint and muscular discomfort improved only in the transdermal estrogen group, whereas heart discomfort and vaginal dryness improved only in the tibolone group. Nevertheless, the intergroup differences in each item were insignificant after adjusting for body mass index and hypertension, which differed before treatment. Conclusions: Both the therapeutic options improved menopausal symptoms within 6 months of use. However, transdermal estrogen appeared to be more effective in preventing weight gain in menopausal women than tibolone. Key Words: Hormone replacement therapy, Menopause, Tibolone, Transdermal estrogens INTRODUCTION placement therapy (HRT) increases blood coagulabil- ity by increasing clotting factor levels and decreasing Menopausal symptoms such as hot flushes, affect up antithrombin activity [3].
    [Show full text]
  • Customs Tariff - Schedule
    CUSTOMS TARIFF - SCHEDULE 99 - i Chapter 99 SPECIAL CLASSIFICATION PROVISIONS - COMMERCIAL Notes. 1. The provisions of this Chapter are not subject to the rule of specificity in General Interpretative Rule 3 (a). 2. Goods which may be classified under the provisions of Chapter 99, if also eligible for classification under the provisions of Chapter 98, shall be classified in Chapter 98. 3. Goods may be classified under a tariff item in this Chapter and be entitled to the Most-Favoured-Nation Tariff or a preferential tariff rate of customs duty under this Chapter that applies to those goods according to the tariff treatment applicable to their country of origin only after classification under a tariff item in Chapters 1 to 97 has been determined and the conditions of any Chapter 99 provision and any applicable regulations or orders in relation thereto have been met. 4. The words and expressions used in this Chapter have the same meaning as in Chapters 1 to 97. Issued January 1, 2020 99 - 1 CUSTOMS TARIFF - SCHEDULE Tariff Unit of MFN Applicable SS Description of Goods Item Meas. Tariff Preferential Tariffs 9901.00.00 Articles and materials for use in the manufacture or repair of the Free CCCT, LDCT, GPT, UST, following to be employed in commercial fishing or the commercial MT, MUST, CIAT, CT, harvesting of marine plants: CRT, IT, NT, SLT, PT, COLT, JT, PAT, HNT, Artificial bait; KRT, CEUT, UAT, CPTPT: Free Carapace measures; Cordage, fishing lines (including marlines), rope and twine, of a circumference not exceeding 38 mm; Devices for keeping nets open; Fish hooks; Fishing nets and netting; Jiggers; Line floats; Lobster traps; Lures; Marker buoys of any material excluding wood; Net floats; Scallop drag nets; Spat collectors and collector holders; Swivels.
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • Pp375-430-Annex 1.Qxd
    ANNEX 1 CHEMICAL AND PHYSICAL DATA ON COMPOUNDS USED IN COMBINED ESTROGEN–PROGESTOGEN CONTRACEPTIVES AND HORMONAL MENOPAUSAL THERAPY Annex 1 describes the chemical and physical data, technical products, trends in produc- tion by region and uses of estrogens and progestogens in combined estrogen–progestogen contraceptives and hormonal menopausal therapy. Estrogens and progestogens are listed separately in alphabetical order. Trade names for these compounds alone and in combination are given in Annexes 2–4. Sales are listed according to the regions designated by WHO. These are: Africa: Algeria, Angola, Benin, Botswana, Burkina Faso, Burundi, Cameroon, Cape Verde, Central African Republic, Chad, Comoros, Congo, Côte d'Ivoire, Democratic Republic of the Congo, Equatorial Guinea, Eritrea, Ethiopia, Gabon, Gambia, Ghana, Guinea, Guinea-Bissau, Kenya, Lesotho, Liberia, Madagascar, Malawi, Mali, Mauritania, Mauritius, Mozambique, Namibia, Niger, Nigeria, Rwanda, Sao Tome and Principe, Senegal, Seychelles, Sierra Leone, South Africa, Swaziland, Togo, Uganda, United Republic of Tanzania, Zambia and Zimbabwe America (North): Canada, Central America (Antigua and Barbuda, Bahamas, Barbados, Belize, Costa Rica, Cuba, Dominica, El Salvador, Grenada, Guatemala, Haiti, Honduras, Jamaica, Mexico, Nicaragua, Panama, Puerto Rico, Saint Kitts and Nevis, Saint Lucia, Saint Vincent and the Grenadines, Suriname, Trinidad and Tobago), United States of America America (South): Argentina, Bolivia, Brazil, Chile, Colombia, Dominican Republic, Ecuador, Guyana, Paraguay,
    [Show full text]
  • Guidelines for Standardization of Bed Rest Studies in the Spaceflight Context
    GUIDELINES FOR STANDARDIZATION OF BED REST STUDIES IN THE SPACEFLIGHT CONTEXT Editors: Patrik Sundblad, Oleg Orlov Contributing authors: Oliver Angerer, Irina Larina, Ronita Cromwell GUIDELINES FOR STANDARDIZATION OF BED REST STUDIES IN THE SPACEFLIGHT CONTEXT International Academy of Astronautics Notice: The cosmic study or position paper that is the subject of this report was approved by the Board of Trustees of the International Academy of Astronautics (IAA). Any opinions, findings, conclusions, or recommendations expressed in this report are those of the authors and do not necessarily reflect the views of the sponsoring or funding organizations. For more information about the International Academy of Astronautics, visit the IAA home page at www.iaaweb.org. Copyright 2014 by the International Academy of Astronautics. All rights reserved. The International Academy of Astronautics (IAA), a non-governmental organization recognized by the United Nations, was founded in 1960. The purposes of the IAA are to foster the development of astronautics for peaceful purposes, to recognize individuals who have distinguished themselves in areas related to astronautics, and to provide a program through which the membership can contribute to international endeavors and cooperation in the advancement of aerospace activities. © International Academy of Astronautics (IAA) June 2014 Study Group report on: Guidelines for Standardization of Bed Rest Studies in the Spaceflight Context Printing of this Study was sponsored by: State Scientific Center of Russian Federation – Institute of Biomedical Problems of the Russian Academy of Sciences (IBMP) 76-A, Khoroshevskoyeshosse, 123007, Moscow, Russia e-mail: [email protected] International Academy of Astronautics 6 rue Galilée, BP 1268-16, 75766 Paris Cedex 16, France Cover Illustration source: NASA Guidelines for Standardization of Bed Rest Studies in the Spaceflight Context Guidelines for Standardization of Bed Rest Table of Content 1.
    [Show full text]
  • Luteal Phase Support Using Oral Dydrogesterone-A Prospective Treatment for Future Replacing Micronized Vaginal Progesterone
    Open Access Journal of Reproductive System and L UPINE PUBLISHERS Sexual Disorders Open Access DOI: 10.32474/OAJRSD.2018.01.000119 ISSN: 2641-1644 Review article Luteal Phase Support using Oral Dydrogesterone-a Prospective Treatment for Future Replacing Micronized Vaginal Progesterone Kulvinder Kochar Kaur1*, Gautam Allahbadia2 and Mandeep Singh3 1Scientific Director, Centre For Human Reproduction, Punjab, India 2Department of Obstetrics and Gynecology, Mumbai, India 3Department of Neurology, Swami Satyanand Hospital, Punjab, India Received: September 03, 2018; Published: September 10, 2018 *Corresponding author: Jalandhar-144001, Punjab, India Kulvinder Kochar Kaur, Scientific Director, Centre For Human Reproduction 721, G.T.B. Nagar, Abstract Although micronized vaginal progesterone is the accepted norm for use in luteal phase support (LPS) in controlled ovarian stimulation (COS) that is used for in vitro fertilization (IVF) cycles, recently importance of oral Dydrogesterone has got the overimportance micronized in lieu vaginal of its progesteroneoral availability, and cheap, it seems no Dcumbersome might soon sidebecome effects the andstandard no definitive of care fornewer LPS fetalin conventional side effects. IVF After cycles the besidesLOTUS 1 its trial routine with indicationa multicenter for recurrentdouble placebo, abortions. double dummy design it has proved an equal efficacy if not superiority of oral D, Keywords: Abbreviations:LPS; COS; IVF; Dydrogesterone; Micronized vaginal progesterone LPS: Luteal Phase Support; COS: Controlled Ovarian Stimulation; IVF: In Vitro Fertilization; ET: Embryo Transfer Dydrogesterone(D)-Pharmacology growth along with corpus luteum formation and maintenance. A potent orally active progesterone receptor agonist D was humans [6], although in recent times 20mg/d of D got used as an Clinically used doses of 5-30mg, they do not suppress ovulation in developed in the1950’s.
    [Show full text]
  • Progestogens and Venous Thromboembolism Among Postmenopausal Women Using Hormone Therapy. Marianne Canonico, Geneviève Plu-Bureau, Pierre-Yves Scarabin
    Progestogens and venous thromboembolism among postmenopausal women using hormone therapy. Marianne Canonico, Geneviève Plu-Bureau, Pierre-Yves Scarabin To cite this version: Marianne Canonico, Geneviève Plu-Bureau, Pierre-Yves Scarabin. Progestogens and venous throm- boembolism among postmenopausal women using hormone therapy.. Maturitas, Elsevier, 2011, 70 (4), pp.354-60. 10.1016/j.maturitas.2011.10.002. inserm-01148705 HAL Id: inserm-01148705 https://www.hal.inserm.fr/inserm-01148705 Submitted on 5 May 2015 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Progestogens and VTE Finale version Progestogens and venous thromboembolism among postmenopausal women using hormone therapy Marianne Canonico1,2, Geneviève Plu-Bureau1,3 and Pierre-Yves Scarabin1,2 1 Centre for Research in Epidemiology and Population Health, U1018, Hormones and Cardiovascular Disease 2 University Paris-Sud, UMR-S 1018, Villejuif, France 3 University Paris Descartes and Hôtel-Dieu Hospital, Paris, France Adresse: 16 av. Paul Vaillant Couturier 94807 Villejuif Cedex Tel: +33 1 45 59 51 66 Fax: +33 1 45 59 51 70 Corresponding author: Marianne Canonico ([email protected]) 1/21 Progestogens and VTE Finale version Abstract Hormone therapy (HT) is the most effective treatment for correcting menopausal symptoms after menopause.
    [Show full text]
  • Prohibited Substances List
    Prohibited Substances List This is the Equine Prohibited Substances List that was voted in at the FEI General Assembly in November 2009 alongside the new Equine Anti-Doping and Controlled Medication Regulations(EADCMR). Neither the List nor the EADCM Regulations are in current usage. Both come into effect on 1 January 2010. The current list of FEI prohibited substances remains in effect until 31 December 2009 and can be found at Annex II Vet Regs (11th edition) Changes in this List : Shaded row means that either removed or allowed at certain limits only SUBSTANCE ACTIVITY Banned Substances 1 Acebutolol Beta blocker 2 Acefylline Bronchodilator 3 Acemetacin NSAID 4 Acenocoumarol Anticoagulant 5 Acetanilid Analgesic/anti-pyretic 6 Acetohexamide Pancreatic stimulant 7 Acetominophen (Paracetamol) Analgesic/anti-pyretic 8 Acetophenazine Antipsychotic 9 Acetylmorphine Narcotic 10 Adinazolam Anxiolytic 11 Adiphenine Anti-spasmodic 12 Adrafinil Stimulant 13 Adrenaline Stimulant 14 Adrenochrome Haemostatic 15 Alclofenac NSAID 16 Alcuronium Muscle relaxant 17 Aldosterone Hormone 18 Alfentanil Narcotic 19 Allopurinol Xanthine oxidase inhibitor (anti-hyperuricaemia) 20 Almotriptan 5 HT agonist (anti-migraine) 21 Alphadolone acetate Neurosteriod 22 Alphaprodine Opiod analgesic 23 Alpidem Anxiolytic 24 Alprazolam Anxiolytic 25 Alprenolol Beta blocker 26 Althesin IV anaesthetic 27 Althiazide Diuretic 28 Altrenogest (in males and gelidngs) Oestrus suppression 29 Alverine Antispasmodic 30 Amantadine Dopaminergic 31 Ambenonium Cholinesterase inhibition 32 Ambucetamide Antispasmodic 33 Amethocaine Local anaesthetic 34 Amfepramone Stimulant 35 Amfetaminil Stimulant 36 Amidephrine Vasoconstrictor 37 Amiloride Diuretic 1 Prohibited Substances List This is the Equine Prohibited Substances List that was voted in at the FEI General Assembly in November 2009 alongside the new Equine Anti-Doping and Controlled Medication Regulations(EADCMR).
    [Show full text]
  • Chapter 231. Poisons and Dangerous Substances Act 1952
    Chapter 231. Poisons and Dangerous Substances Act 1952. Certified on: / /20 . INDEPENDENT STATE OF PAPUA NEW GUINEA. Chapter 231. Poisons and Dangerous Substances Act 1952. ARRANGEMENT OF SECTIONS. PART I – PRELIMINARY. 1. Interpretation. “automatic machine” “the British Pharmacopoeia” “container” “dangerous substance” “methylated spirit” “package” “poison” “poisons licence” “Poisons Register” “rectified spirit” “the regulations” “sell” “this Act” 2. Application. 3. Calculations of percentages. 4. Variation of schedules. PART II – LICENCES. 5. Poisons licence. 6. Revocation of poisons licences. PART III – SALE OF POISONS AND DANGEROUS SUBSTANCES. 7. Application of Part III to wholesalers. 8. Sale of things specified in Schedules 1 and 2. 9. Sale, etc., of things specified in Schedule 1. 10. Sale of things specified in Schedule 3. 11. Sale of things specified in Schedule 4. 12. Sale of things specified in Schedule 5. 13. Hawking poisons and dangerous substances. 14. Sale of poisons to persons under 18 years, etc. 15. Automatic vending machines. 16. Poisons Registers. 17. Entries in Poisons Registers. 18. Person unable to sign his name. 19. Sale on order by letter, etc. 20. Sale to medical practitioners, etc. 21. Application of Sections 14, 17, 18 and 19. 22. Records to be kept by medical practitioners, etc. PART IV – LABELLING AND PACKING POISONS AND DANGEROUS SUBSTANCES. 23. Sale of poisons and dangerous substances. 24. Sale of liquid dangerous substances. 25. Colouring of methylated spirits. 26. Sale of poisons. PART V – MISCELLANEOUS. 27. Drinking of methylated spirit prohibited. 28. Methylated spirit not to be sold for drinking purposes. 29. Inspection. 30. Offences in relation to the sale of poisons, etc.
    [Show full text]
  • The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
    WHO/PSM/QSM/2006.3 The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances 2006 Programme on International Nonproprietary Names (INN) Quality Assurance and Safety: Medicines Medicines Policy and Standards The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 © World Health Organization 2006 All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: [email protected]). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.
    [Show full text]